These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 18457951)
1. Indirect oxidation of the antitumor agent procarbazine by tyrosinase--possible application in designing anti-melanoma prodrugs. Gasowska-Bajger B; Wojtasek H Bioorg Med Chem Lett; 2008 Jun; 18(11):3296-300. PubMed ID: 18457951 [TBL] [Abstract][Full Text] [Related]
2. Oxidation of carbidopa by tyrosinase and its effect on murine melanoma. Gasowska-Bajger B; Frackowiak-Wojtasek B; Koj S; Cichoń T; Smolarczyk R; Szala S; Wojtasek H Bioorg Med Chem Lett; 2009 Jul; 19(13):3507-10. PubMed ID: 19457668 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines. Monteiro AS; Almeida J; Cabral G; Severino P; Videira PA; Sousa A; Nunes R; Pereira JD; Francisco AP; Perry MJ; Mendes E Eur J Med Chem; 2013; 70():1-9. PubMed ID: 24125877 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and analysis of activity of a potential anti-melanoma prodrug with a hydrazine linker. Frąckowiak-Wojtasek B; Gąsowska-Bajger B; Mazurek M; Raniszewska A; Logghe M; Smolarczyk R; Cichoń T; Szala S; Wojtasek H Eur J Med Chem; 2014 Jan; 71():98-104. PubMed ID: 24287558 [TBL] [Abstract][Full Text] [Related]
5. Indirect oxidation of amino acid phenylhydrazides by mushroom tyrosinase. Gasowska B; Frackowiak B; Wojtasek H Biochim Biophys Acta; 2006 Sep; 1760(9):1373-9. PubMed ID: 16784814 [TBL] [Abstract][Full Text] [Related]
6. Melanocyte-Directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma. Jordan AM; Khan TH; Malkin H; Osborn HM; Photiou A; Riley PA Bioorg Med Chem; 2001 Jun; 9(6):1549-58. PubMed ID: 11408174 [TBL] [Abstract][Full Text] [Related]
7. Dopamine- and tyramine-based derivatives of triazenes: activation by tyrosinase and implications for prodrug design. Perry MJ; Mendes E; Simplício AL; Coelho A; Soares RV; Iley J; Moreira R; Francisco AP Eur J Med Chem; 2009 Aug; 44(8):3228-34. PubMed ID: 19386398 [TBL] [Abstract][Full Text] [Related]
8. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Gili A; Thomas PD; Ota M; Jimbow K Melanoma Res; 2000 Feb; 10(1):9-15. PubMed ID: 10711635 [TBL] [Abstract][Full Text] [Related]
9. Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. Swaffar DS; Horstman MG; Jaw JY; Thrall BD; Meadows GG; Harker WG; Yost GS Cancer Res; 1989 May; 49(9):2442-7. PubMed ID: 2706632 [TBL] [Abstract][Full Text] [Related]
10. The mitochondrial metabolism of 1,2-disubstituted hydrazines, procarbazine and 1,2-dimethylhydrazine. Coomes MW; Prough RA Drug Metab Dispos; 1983; 11(6):550-5. PubMed ID: 6140138 [TBL] [Abstract][Full Text] [Related]
11. Discovery of small-molecule inhibitors of tyrosinase. Germanas JP; Wang S; Miner A; Hao W; Ready JM Bioorg Med Chem Lett; 2007 Dec; 17(24):6871-5. PubMed ID: 17964155 [TBL] [Abstract][Full Text] [Related]
12. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Riley PA; Cooksey CJ; Johnson CI; Land EJ; Latter AM; Ramsden CA Eur J Cancer; 1997 Jan; 33(1):135-43. PubMed ID: 9071913 [TBL] [Abstract][Full Text] [Related]
13. Tyrosinase-mediated oxidation of acetaminophen to 4-acetamido-o-benzoquinone. Valero E; Varón R; García-Carmona F Biol Chem; 2002 Dec; 383(12):1931-9. PubMed ID: 12553730 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and preliminary in vitro biological evaluation of 4-[(4-hydroxyphenyl)sulfanyl]but-3-en-2-one, a 4-mercaptophenol derivative designed as a novel bifunctional antimelanoma agent. Ruzza P; Rosato A; Nassi A; Rondina M; Zorzin M; Rossi CR; Floreani M; Quintieri L J Med Chem; 2009 Aug; 52(15):4973-6. PubMed ID: 19601648 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. Ferguson J; Rogers PM; Kelland LR; Robins DJ Oncol Res; 2005; 15(2):87-94. PubMed ID: 16119006 [TBL] [Abstract][Full Text] [Related]
16. Effects of mushroom tyrosinase on anisaldehyde. Ha TJ; Tamura S; Kubo I J Agric Food Chem; 2005 Sep; 53(18):7024-8. PubMed ID: 16131106 [TBL] [Abstract][Full Text] [Related]
17. New prodrugs derived from 6-aminodopamine and 4-aminophenol as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT). Knaggs S; Malkin H; Osborn HM; Williams NA; Yaqoob P Org Biomol Chem; 2005 Nov; 3(21):4002-10. PubMed ID: 16240021 [TBL] [Abstract][Full Text] [Related]
18. Oxidation products of quercetin catalyzed by mushroom tyrosinase. Kubo I; Nihei K; Shimizu K Bioorg Med Chem; 2004 Oct; 12(20):5343-7. PubMed ID: 15388161 [TBL] [Abstract][Full Text] [Related]
20. Effects of the immobilization supports on the catalytic properties of immobilized mushroom tyrosinase: a comparative study using several substrates. Marín-Zamora ME; Rojas-Melgarejo F; García-Cánovas F; García-Ruiz PA J Biotechnol; 2007 Sep; 131(4):388-96. PubMed ID: 17868943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]